These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21233638)

  • 1. Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.
    Depatureaux A; Charpentier C; Leoz M; Unal G; Damond F; Kfutwah A; Vessière A; Simon F; Plantier JC
    J Acquir Immune Defic Syndr; 2011 Feb; 56(2):139-45. PubMed ID: 21233638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes.
    De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G
    Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS).
    Scherrer AU; Hasse B; von Wyl V; Yerly S; Böni J; Bürgisser P; Klimkait T; Bucher HC; Ledergerber B; Günthard HF
    HIV Med; 2009 Nov; 10(10):647-56. PubMed ID: 19732174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnosis and monitoring of HIV-1 group O-infected patients in Cameroun.
    Vessière A; Rousset D; Kfutwah A; Leoz M; Depatureaux A; Simon F; Plantier JC
    J Acquir Immune Defic Syndr; 2010 Jan; 53(1):107-10. PubMed ID: 19770803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV type-1 group O infection in Gabon: low prevalence rate but circulation of genetically diverse and drug-resistant HIV type-1 group O strains.
    Liégeois F; Boué V; Butel C; Mouinga-Ondémé A; Sica J; Zamba C; Peeters M; Delaporte E; Rouet F
    AIDS Res Hum Retroviruses; 2013 Jul; 29(7):1085-90. PubMed ID: 23409798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.
    Poonpiriya V; Sungkanuparph S; Leechanachai P; Pasomsub E; Watitpun C; Chunhakan S; Chantratita W
    J Virol Methods; 2008 Jul; 151(1):79-86. PubMed ID: 18462814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.
    Vergne L; Peeters M; Mpoudi-Ngole E; Bourgeois A; Liegeois F; Toure-Kane C; Mboup S; Mulanga-Kabeya C; Saman E; Jourdan J; Reynes J; Delaporte E
    J Clin Microbiol; 2000 Nov; 38(11):3919-25. PubMed ID: 11060045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.
    Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L
    J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
    Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
    J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
    Maïga AI; Descamps D; Morand-Joubert L; Malet I; Derache A; Cisse M; Koita V; Akonde A; Diarra B; Wirden M; Tounkara A; Verlinden Y; Katlama C; Costagliola D; Masquelier B; Calvez V; Marcelin AG
    Antimicrob Agents Chemother; 2010 Feb; 54(2):728-33. PubMed ID: 20008779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.
    Guo W; Han J; Zhuang D; Liu S; Liu Y; Li L; Li H; Bao Z; Wang F; Li J
    Virol J; 2015 Nov; 12():187. PubMed ID: 26578099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of the virological response to etravirine in clinical practice: Comparison of three genotype algorithms.
    Cotte L; Trabaud MA; Tardy JC; Brochier C; Gilibert RP; Miailhes P; Trépo C; André P
    J Med Virol; 2009 Apr; 81(4):672-7. PubMed ID: 19235860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
    Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
    Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study.
    Costagliola D; Descamps D; Assoumou L; Morand-Joubert L; Marcelin AG; Brodard V; Delaugerre C; Mackiewicz V; Ruffault A; Izopet J; Plantier JC; Tamalet C; Yerly S; Saidi S; Brun-Vezinet F; Masquelier B;
    J Acquir Immune Defic Syndr; 2007 Sep; 46(1):12-8. PubMed ID: 17514016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Algorithms for the interpretation of HIV-1 genotypic drug resistance information.
    Vercauteren J; Vandamme AM
    Antiviral Res; 2006 Sep; 71(2-3):335-42. PubMed ID: 16782210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy.
    Rousseau MN; Vergne L; Montes B; Peeters M; Reynes J; Delaporte E; Segondy M
    J Acquir Immune Defic Syndr; 2001 Jan; 26(1):36-43. PubMed ID: 11176267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of HIV-1 drug resistance among patients failing first-line ART in Monrovia, Liberia: a cross-sectional study.
    Loubet P; Charpentier C; Visseaux B; Borbor A; Nuta C; Adu E; Chapplain JM; Baysah M; Tattevin P; Yazdanpanah Y; Descamps D
    J Antimicrob Chemother; 2015; 70(6):1881-4. PubMed ID: 25698771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.